zurück zur Startseite
Zentrale Tel.: 06221-560

Arbeitsgruppe Neuro-RadioOnkologie

Team

Arbeitsgruppenleiterin:

Dr. med. Angela Mohr

Arbeitsgruppe RadioOnkologie – Gliome

Arbeitsgruppenleiter:
Dr. med. Sebastian Adeberg

Wissenschaftliche Mitarbeiter:

PD Dr. med. Stefan Rieken
Dr. med. Henrik Hauswald
Dr. med. Semi B. Harrabi
Dr. med. Denise Bernhardt
Dr. med. Tilman Bostel
Nina Bougatf
Lena Orschiedt
Sigrid Daffinger
Eric Tonndorf-Martini
Dr. med. Tanja Sprave, MBA
Mustafa Syed
Jakob Liermann

Doktoranden:

Sebastian Regnery (cand.med.) 

 


Kontakt

Schriftliche Anfrage:

Universitätsklinikum Heidelberg
Abteilung für RadioOnkologie und Strahlentherapie
Anfragemanagement
Im Neuenheimer Feld 400
69120 Heidelberg
Opens window for sending emailE-Mail


Aufbau der Arbeitsgruppe

Exemplarisches Dosis-Volumen-Histogramm eines FSRT-Planes unter Anwendung von Protonen. Signifikante Reduzierung der Gesamtdosis und somit potentielle Reduzierung von Langzeitnebenwirkungen. (Harrabi et al. Radiat. Oncol. 2014)

In enger Kooperation mit den Abteilungen Neuroonkologie, Neuropathologie, Neuroradiologie und Neurochirurgie werden moderne Studienkonzepte zur Behandlung von Hirneigenen Tumoren nach Erstdiagnose, sowie in der Rezidivsituation untersucht.

Die Arbeitsgruppe Neuro-Radioonkologie ist vier Bereiche gegliedert:


Ausgewählte Literatur

    1. Harrabi SB, Bougatf N, Mohr A, Haberer T, Herfarth K, Combs SE, Debus J, Adeberg S: Dosimetric advantages of proton therapy over conventional radiotherapy with photons in young patients and adults with low-grade glioma. Strahlenther Onkol. 2016 Jun 30.
    2. Adeberg S, Harrabi SB, Bougatf N, Bernhardt D, Rieber J, Koerber SA, Syed M, Sprave T, Mohr A, Abdollahi A, Haberer T, Combs SE, Herfarth K, Debus J, Rieken S. Intensity-modulated proton therapy, volumetric-modulated arc therapy, and 3D conformal radiotherapy in anaplastic astrocytoma and glioblastoma : A dosimetric comparison. Strahlenther Onkol. 2016 Jun 22.
    3. Adeberg S, Bernhardt D, Harrabi SB, Diehl C, Koelsche C, Rieken S, Unterberg A, von Deimling A, Debus J.: Radiotherapy plus concomitant temozolomide in primary gliosarcoma. J Neurooncol. 2016 Jun;128(2):341-8.
    4. Adeberg S, Diehl C, Jung CS, Rieken S, Combs SE, Unterberg A, Debus J: Is a modification of the radiotherapeutic target volume necessary after resection of glioblastomas with opening of the ventricles? J Neurooncol. 2016 May;127(3):581-7.
    5. Harrabi SB, Adeberg S, Winter M, Haberer T, Debus J, Weber KJ:S-phase-specific radiosensitization by gemcitabine for therapeutic carbon ion exposure in vitro. J Radiat Res. 2016 Mar;57(2):110-4.
    6. Adeberg S, Bernhardt D, Ben Harrabi S, Bostel T, Mohr A, Koelsche C, Diehl C, Rieken S, Debus J: Metformin influences progression in diabetic glioblastoma patients. Strahlenther Onkol. 2015 Dec;191(12):928-35.

    7. Rieken S, Rieber J, Brons S, Habermehl D, Rief H, Orschiedt L, Lindel K, Weber KJ, Debus J, Combs SE: Radiation-induced motility alterations in medulloblastoma cells. Journal of radiation research 2015, 56(3):430-436.
    8. Hauswald H, Stenke A, Debus J, Combs SE: Linear accelerator-based stereotactic radiosurgery in 140 brain metastases from malignant melanoma. BMC cancer 2015, 15:537.
      Adeberg S, Bostel T, Harrabi S, Bernhardt D, Welzel T, Wick W, Debus J, Combs SE: Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastoma. BMC cancer 2015, 15(1):558.
    9. Adeberg S, Bernhardt D, Foerster R, Bostel T, Koerber SA, Mohr A, Koelsche C, Rieken S, Debus J: The influence of hyperglycemia during radiotherapy on survival in patients with primary glioblastoma. Acta oncologica 2015:1-7.
    10. Harrabi SB, Adeberg S, Welzel T, Rieken S, Habermehl D, Debus J, Combs SE: Long term results after fractionated stereotactic radiotherapy (FSRT) in patients with craniopharyngioma: maximal tumor control with minimal side effects. Radiation oncology 2014, 9:203.
      Adeberg S, Konig L, Bostel T, Harrabi S, Welzel T, Debus J, Combs SE: Glioblastoma recurrence patterns after radiation therapy with regard to the subventricular zone. Int J Radiat Oncol Biol Phys 2014, 90(4):886-893.
    11. Adeberg S, Bostel T, Konig L, Welzel T, Debus J, Combs SE: A comparison of long-term survivors and short-term survivors with glioblastoma, subventricular zone involvement: a predictive factor for survival? Radiation oncology 2014, 9:95.
    12. Rieken S, Habermehl D, Welzel T, Mohr A, Lindel K, Debus J, Combs SE: Long term toxicity and prognostic factors of radiation therapy for secreting and non-secreting pituitary adenomas. Radiation oncology 2013, 8:18.
    13. Rieken S, Habermehl D, Giesel FL, Hoffmann C, Burger U, Rief H, Welzel T, Haberkorn U, Debus J, Combs SE: Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2013, 109(3):487-492.
    14. Hauswald H, Habl G, Krug D, Kehle D, Combs SE, Bermejo JL, Debus J, Sterzing F: Whole brain helical Tomotherapy with integrated boost for brain metastases in patients with malignant melanoma-a randomized trial. Radiation oncology 2013, 8:234.
    15. Harrabi S, Combs SE, Brons S, Haberer T, Debus J, Weber KJ: Temozolomide in combination with carbon ion or photon irradiation in glioblastoma multiforme cell lines - does scheduling matter? International journal of radiation biology 2013, 89(9):692-697.
    16. Rieken S, Habermehl D, Wuerth L, Brons S, Mohr A, Lindel K, Weber K, Haberer T, Debus J, Combs SE: Carbon ion irradiation inhibits glioma cell migration through downregulation of integrin expression. International journal of radiation oncology, biology, physics 2012, 83(1):394-399.
    17. Rieken S, Habermehl D, Haberer T, Jaekel O, Debus J, Combs SE: Proton and carbon ion radiotherapy for primary brain tumors delivered with active raster scanning at the Heidelberg Ion Therapy Center (HIT): early treatment results and study concepts. Radiation oncology 2012, 7:41.
    18. Hauswald H, Rieken S, Ecker S, Kessel KA, Herfarth K, Debus J, Combs SE: First experiences in treatment of low-grade glioma grade I and II with proton therapy. Radiation oncology 2012, 7:189.
    19. Hauswald H, Dittmar JO, Habermehl D, Rieken S, Sterzing F, Debus J, Combs SE: Efficacy and toxicity of whole brain radiotherapy in patients with multiple cerebral metastases from malignant melanoma. Radiation oncology 2012, 7:130.
    20. Adeberg S, Hartmann C, Welzel T, Rieken S, Habermehl D, von Deimling A, Debus J, Combs SE: Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas--clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. International journal of radiation oncology, biology, physics 2012, 83(3):859-864.
    21. Rieken S, Mohr A, Habermehl D, Welzel T, Lindel K, Witt O, Kulozik AE, Wick W, Debus J, Combs SE: Outcome and prognostic factors of radiation therapy for medulloblastoma. International journal of radiation oncology, biology, physics 2011, 81(3):e7-e13.
    22. Rieken S, Habermehl D, Nikoghosyan A, Jensen A, Haberer T, Jakel O, Munter MW, Welzel T, Debus J, Combs SE: Assessment of early toxicity and response in patients treated with proton and carbon ion therapy at the Heidelberg ion therapy center using the raster scanning technique. Int J Radiat Oncol Biol Phys 2011, 81(5):e793-801.
    23. Rieken S, Habermehl D, Mohr A, Wuerth L, Lindel K, Weber K, Debus J, Combs SE: Targeting alphanubeta3 and alphanubeta5 inhibits photon-induced hypermigration of malignant glioma cells. Radiation oncology 2011, 6:132.
    24. Adeberg S, Welzel T, Rieken S, Debus J, Combs SE: Prior surgical intervention and tumor size impact clinical outcome after precision radiotherapy for the treatment of optic nerve sheath meningiomas (ONSM). Radiation oncology 2011, 6:117.
    25. Rieken S, Gaiser T, Mohr A, Welzel T, Witt O, Kulozik AE, Wick W, Debus J, Combs SE: Outcome and prognostic factors of desmoplastic medulloblastoma treated within a multidisciplinary treatment concept. BMC cancer 2010, 10:450.
    Select languageSelect language
    Print Diese Seite per E-Mail weiterempfehlen